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Abstract 16 
Importance: The likelihood of achieving a live-birth with repeat in-vitro fertilisation (IVF) is 17 
unclear, yet treatment is commonly limited to three or four embryo transfers. 18 
Objective: To determine the live-birth rate per initiated IVF cycle and with repeated cycles. 19 
Design, Setting and Participants: Prospective study of 156,947 UK women who received 20 
257,398 IVF ovarian stimulation cycles between 2003 and 2010 and were followed until June 21 
2012. 22 
Main exposure: IVF, with a cycle defined as an episode of ovarian stimulation and all 23 
subsequent separate fresh and frozen embryo transfers. 24 
Main Outcome(s): Live-birth rate per IVF cycle and the cumulative live-birth rates across all 25 
cycles in all women and by age and treatment type. Optimal, prognosis-adjusted and 26 
conservative cumulative live-birth rates were estimated, reflecting 0%, 30% and 100% of 27 
women discontinuing due to poor prognosis and having a live-birth rate of zero had they 28 
continued. 29 
Results: In all women the live-birth rate for the first cycle was 29.5% (95%CI: 29.3, 29.7). 30 
This remained above 20% up to and including the fourth cycle. The cumulative prognosis-31 
adjusted live-birth rate across all cycles continued to increase up to the ninth, with 65.3% 32 
(64.8, 65.8) of women achieving a live-birth by the sixth cycle. In women younger than 40 33 
using their own oocytes, the live-birth rate for the first cycle was 32.3% (32.0, 32.5), and 34 
remained above 20% up to and including the fourth cycle. Six cycles achieved a cumulative 35 
prognosis-adjusted live-birth rate of 68.4% (67.8, 68.9). For women aged 40-42, the live-birth 36 
rate for the first cycle was 12.3% (95%CI: 11.8, 12.8), with six cycles achieving a cumulative 37 
prognosis-adjusted live-birth rate of 31.5% (29.7, 33.3). For women older than 42 years all 38 
rates within each cycle were less than 4%. No age differential was observed among women 39 
using donor oocytes. Rates were lower in those with untreated male factor infertility 40 
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compared to those with any other cause, but treatment with either intra-cytoplasmic sperm 41 
injection or sperm donation removed this difference. 42 
Conclusions and relevance: Among women in the UK undergoing IVF, the cumulative 43 
prognosis-adjusted live-birth rate after six cycles was 65.3%, with variations by age and 44 
treatment type. These findings support the efficacy of extending the number of IVF cycles 45 
beyond three or four.  46 
 47 
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Introduction 48 
In-vitro fertilization (IVF) is commonly stopped after three or four unsuccessful embryo 49 
transfers,1,2 with three unsuccessful transfers labelled ‘repeat implantation failure’.3 This 50 
practice has been influenced by a study of 1,328 embryo transfers undertaken twenty-years 51 
ago, without use of intra-cytoplasmic sperm injection (ICSI), which reported a decline in 52 
live-birth rates after the fourth cycle.4 With one exception,5 previous studies of cumulative 53 
pregnancy or live-birth rates have been relatively small, with limited ability to precisely 54 
estimate cumulative success beyond four transfers.4,6-9  Previous studies have defined a cycle 55 
of IVF as an embryo transfer.5-9 Thus, each initiation of IVF with ovarian stimulation has 56 
been treated as several separate cycles whenever there has been a series of repeated embryo 57 
transfers. Given the promotion of single embryo transfer and the effective freezing of 58 
embryos have increased markedly over the last 10-15 years,10-15 it has been suggested that 59 
IVF success should be calculated as the live-birth rate per initiated ovarian stimulation, 60 
including all subsequent separate fresh and frozen embryo transfers.5,10-13  61 
 62 
The aim of this study was to determine the extent to which repeat IVF cycles continue to 63 
increase the likelihood of a live-birth, defining an IVF cycle as the initiation of treatment with 64 
ovarian stimulation and all resulting separate fresh or frozen embryo transfers; hereafter we 65 
use the term “cycle” for this. Specific objectives were to determine: (i) the live-birth rate 66 
within each cycle, and the cumulative rate across all cycles; (ii) how these varied by age and 67 
treatment types (use of donor oocyte, ICSI or sperm donation); and (iii) the association 68 
between oocyte yield in one cycle and live-birth rate in subsequent cycles.  69 
 70 
Methods 71 
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Ethical approval for this study was provided by the UK Human Fertilisation and Embryology 72 
Authority (HFEA) who have statutory obligations to prospectively collect information on all 73 
assisted reproductive treatment (ART) in the UK. Women provided written consent for this 74 
information to be used in analyses, audit and publications. The HFEA provided us with data 75 
on all ART events occurring in the UK between 1st January 2003 and 30th June 2012, with 76 
linkage of cycles to individual women and data on birth outcomes. Because all UK clinics, 77 
whether private or public, must provide information on any patients treated with ART, 78 
together with the outcomes of that treatment, to the HFEA, they are able to link cycles to 79 
individual women for all UK ART. We chose the 2003 start date in order to obtain a large 80 
cohort representative of contemporary treatment, and June 2012 was the latest date for which 81 
the HFEA could provide validated data. Because the live-birth outcome data were incomplete 82 
for cycles commencing between January 2011 and June 2012 (as many of these cycles were 83 
still continuing and births from them could occur after June 2012) we limited our potentially 84 
eligible cohort to ovarian stimulation cycles initiated between 1st January 2003 and 31st 85 
December 2010, with live-birth outcome data collected up to June 2012.  86 
 87 
We excluded ART that was not IVF or was undertaken for the purpose of storage, donation 88 
or surrogacy. We excluded women who had started IVF before 2003. As in other studies,5-9 89 
once a live-birth occurred women were censored from further analysis. To reflect clinical 90 
practice and allow comparisons with other studies,4,5,7,9 we included all embryo transfers, 91 
whether the individual transfer was of one or more embryos. 92 
 93 
Live-birth was defined as an infant born alive after 24 weeks gestation surviving more than 94 
one month. The World Health Organisation (WHO) define live-birth as a birth showing any 95 
sign of life irrespective of gestational age. As in other studies,5, 15,16 we modified this to 96 
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capture births that were likely to be viable. We defined an IVF cycle as the initiation of 97 
ovarian stimulation and all resulting separate fresh or frozen embryo transfers. The live-birth 98 
rate within a cycle was defined as the probability of a live-birth from an ovarian stimulation 99 
encompassing all subsequent fresh and frozen embryo transfers from that stimulation. Thus, 100 
for those embarking on IVF the live-birth rate within one cycle answers the question ‘What is 101 
my chance of a live-birth with one stimulation and retrieval of oocytes followed by as many 102 
subsequent separate embryo transfers as possible from that retrieval?’ The cumulative live-103 
birth rate at a given cycle was defined as the probability of a live-birth from all cycles up to 104 
and including that cycle. This answers the question ‘What is my total chance of a live-birth 105 
with repeat ovarian stimulation and oocyte retrievals, together with the subsequent embryo 106 
transfers from each cycle, up to a given cycle number?’.  107 
 108 
Information on age, types of treatment (oocyte donation, sperm donation and ICSI), oocyte 109 
yield and other couple characteristics were obtained from the HFEA dataset. 110 
 111 
Statistical methods 112 
We calculated the live-birth rates within the first and subsequent cycles up to the ninth, as the 113 
proportion of cycles resulting in a live-birth, using a normal approximation to construct 114 
confidence intervals. We calculated estimates of cumulative live-birth rates using different 115 
assumptions of women who discontinue IVF without a live birth (see below), up to the ninth 116 
cycle, using the Kaplan-Meier method with Greenwood’s approximation to calculate 117 
confidence intervals (see online supplementary material for full details).17,18 We used a log-118 
rank test19 to compare the live-birth rate within each cycle and cumulatively across all cycles. 119 
The first set of comparisons was between woman’s age and oocyte source category and the 120 
second was between no male cause of infertility and male cause of infertility with and 121 
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without treatment by ICSI or sperm donation. We assessed the relationship of oocyte yield in 122 
one cycle to live-birth rates in subsequent cycles in women younger than 40 years using their 123 
own oocytes, by calculating the within live-birth rate in the first, second, and third cycles by 124 
oocytes retrieved in the first cycle, and also calculating the within live-birth rate up to the 125 
fifth cycle by oocytes retrieved in the immediately preceding cycle. 126 
 127 
Dealing with discontinuation of IVF 128 
Infertile couples discontinue IVF for a number of reasons, with a systematic review of patient 129 
perceptions concluding that the commonest reasons were the physical and/or psychological 130 
burden of treatment, relationship or personal problems.20 In any study estimating cumulative 131 
live-birth rates assumptions have to be made about what the rate in those who discontinue 132 
would have been had they continued. To account for this we calculated ‘optimal’ and 133 
‘conservative’ estimates, which are the have been assessed in previous studies. In addition we 134 
calculated a prognostic-adjusted estimate. The optimal estimate, is based on the observed 135 
data, and whilst not always explicit in previous publications, this assumes that the cumulative 136 
live-birth rate in women who discontinue IVF without a live-birth, if they had continued 137 
would be equal to the rate in those who continue to have further cycles.5 The conservative 138 
estimate assumes those who discontinue IVF would have had a subsequent live-birth rate of 139 
zero.5 The true rate is thought to lie between these two.7 The prognostic-adjusted estimate 140 
aims to obtain this more realistic value. It assumes a fixed proportion of those who 141 
discontinue do so because of poor prognosis and that the live-birth rate in that proportion 142 
would have been zero, whereas for those who discontinue for other reasons, such as inability 143 
to pay, emotional distress or (in our dataset) emigration from the UK, it would have been 144 
similar to those who continue with treatment.  145 
 146 
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For the prognosis-adjusted estimate we considered the woman’s age at her first cycle and 147 
oocyte yield in the previous cycle to be the strongest prognostic factors, because these have 148 
been shown to be strongly related to live-birth success.5,7,9,21,22 We checked that these were 149 
indicators of live-birth and of discontinuation of treatment in our own data, as well as 150 
comparing other available characteristics between those who discontinued and continued 151 
treatment after one unsuccessful cycle. To obtain age-adjusted and oocyte yield-adjusted 152 
estimates we calculated results for each age strata (18-34, 35-37, 38-39, 40-42, 43-44, 45-50, 153 
50+ years) and for each possible oocyte-yield in the previous cycle and then obtained an 154 
average, weighted by the numbers within each category in the first cycle. It was not possible 155 
to calculate an age-adjusted estimates for the age stratified analyses as there is too little age 156 
variation within the age strata. For any analyses that include women using donor oocytes it is 157 
not possible to calculate rates adjusted for oocyte yield in the previous cycle as women using 158 
donor oocytes will not have an oocyte yield. 159 
 160 
The age and previous oocyte yield adjusted results suggested that 3% of those who 161 
discontinued IVF did so because of poor prognosis. However, to calculate a prognostic-162 
adjusted cumulative live-birth rate we assumed 30% of those who discontinued did so 163 
because of poor prognosis. We chose a value of ten-times that suggested by our data to obtain 164 
a conservative prognostic-adjusted estimate. Full details of how these estimates were 165 
calculated are provided in online supplementary material. 166 
 167 
As the average population live-birth success rate for a single embryo transfer is between 20-168 
30% in high income countries,10-13 we considered 20% to be a benchmark for a good live-169 
birth rate within a cycle. All analyses were undertaken in Stata version 13 MP2. Two-sided p-170 
values < 0.05 were considered to provide evidence against the null hypothesis. 171 
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 172 
Comparison with live-birth rates in those not receiving ART 173 
We used data on pregnancy and pregnancy loss rates from published literature to estimate 174 
live-birth rates in women who conceive naturally.23-254 Two prospective cohort studies of 175 
couples actively trying to conceive provided age specific pregnancy rates attained within 176 
twelve menstrual cycles.23,24 Live birth rates were calculated assuming 20% of natural 177 
conceptions result in a pregnancy loss.25 178 
 179 
Results 180 
Following planned exclusions the eligible cohort included 257,665 cycles in 157,475 women. 181 
For all analyses we excluded women with missing linkage information or implausible linkage 182 
(i.e. first IVF transfer being a frozen embryo transfer without preceding ovarian stimulation). 183 
This resulted in an analysis cohort of 257,398 cycles by 156,947 women (more than 99% of 184 
the eligible cohort; Figure 1). Table 1 shows the characteristics of the cohort. eTable 1 185 
shows characteristics by year of treatment. Because of the large sample size there was 186 
statistical evidence of differences in all characteristics, but for most these were small and 187 
unlikely to be clinically important. For example, median age of the women differed by one-188 
year and median oocyte retrieval differed by one across the study period. Use of ICSI 189 
increased by 11%, and transfer of single embryos by 17%, though the live-birth rate increased 190 
by just two-percent across the study period.  191 
 192 
Table 2 shows the live-birth rate within each cycle for the whole cohort. In all women the 193 
live-birth rate for the first cycle was 29.5% (95%CI: 29.3, 29.7). The live-birth rate within 194 
cycles remained above 20% for each cycle up to and including the fourth. After their first 195 
cycle there were 110,614 women (70.5% of the analysis cohort) who did not have a live-196 
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birth. Of these, 37,704 (34.1%) discontinued treatment and 72,910 (65.9%) had at least one 197 
more cycle. eTable 2 compares characteristics between these two groups. Although there was 198 
statistical evidence of differences for all characteristics the actual differences were small.  199 
 200 
The cumulative live-birth rate continued to increase up to the ninth cycle, with a cumulative 201 
prognosis-adjusted live-birth rate of 65.3% (64.8, 65.8) by the sixth cycle (Table 2). The 202 
equivalent optimal (78.0% (77.3, 78.8)) and age-adjusted (76.7% (76.0, 77.5)) estimates for 203 
six cycles were similar, while the conservative estimate was 46.8% (46.5, 47.0) (Table 2 and 204 
eFigure 1).  205 
 206 
Results varied by age and oocyte source (Figure 2, Table 3, eTables 3 and 4). In women 207 
who were younger than 40 years and using their own oocytes (133,379 women, 85% of the 208 
cohort), the live-birth rate for the first cycle was 32.3% (32.0, 32.5). This remained above 209 
20% up to and including the fourth cycle. The previous cycle oocyte-yield adjusted and 210 
optimal estimates were similar. Six cycles achieved cumulative live-birth rates of 68.4%, 211 
(67.8, 68.9), 80.3% (79.5 to 81.0) and 50.7% (50.5, 51.0), for the prognostic-adjusted, 212 
optimal and conservative estimates, respectively. For women aged 40-42, the live-birth rate 213 
for the first cycle was 12.3% (11.8, 12.8), with six cycles achieving a cumulative live-birth 214 
rates of 31.5% (29.7, 33.3), 41.5% (38.0, 44.9), and 19.2% (18.5, 19.8) for prognostic-215 
adjusted, optimal and conservative estimates, respectively. For women older than 42 years all 216 
rates within each cycle were less than 4% or based on too few live-births to calculate 217 
confidence intervals.  218 
 219 
Use of donor oocytes removed this age differential, as the log-rank test showed no evidence 220 
for different cumulative live-birth rates between age categories (eTable 3). Irrespective of 221 
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age, women using donor oocytes achieved live-birth rates within each cycle of  29.6% or 222 
greater for all cycles up to and including the ninth and a cumulative live-birth rate after six 223 
cycles of 86.7% (85.2, 88.3), 91.7% (90.3, 93.1) and 75.5% (74.0, 77.1) for the prognostic-224 
adjusted, optimal and conservative estimates, respectively (eTable 4).  225 
 226 
Live-birth rates varied by male cause infertility and its treatment (Figure 3 and eTables 5 to 227 
7). Women whose infertility was due to a male related cause and who were not treated with 228 
either ICSI or donor sperm had lower live-birth rates than those with a non-male cause of 229 
infertility (eTables 3 and 5). Those with a male cause of infertility who were treated with 230 
ICSI had cumulative live-birth rates, after six cycles, of 71.3% (70.5, 72.1), 82.2% (81.1, 231 
83.4) and 54.7% (54.3, 55.2) using the prognostic-adjusted, optimal and conservative, 232 
estimates, respectively (eTable 6). Equivalent results for those with male infertility treated 233 
with donor sperm were 81.2% (78.6, 83.9), 90.2% (87.2, 93.1) and 65.9% (63.9, 67.9)  234 
respectively (eTable 7). Live-birth rates in both of these groups were greater than in those 235 
with a non-male cause of infertility (eTables 3 and 8).  236 
 237 
Figure 4 shows the live-birth rate within the first, second and third cycles plotted against the 238 
number of oocytes retrieved in the first cycle in women under 40 years of age using their own 239 
oocytes. For those in whom no oocytes were retrieved in the first cycle the live-birth rates in 240 
the second and third cycles were greater than 20%. The live-birth rates in the first, second and 241 
third cycles continued to increase with increasing oocytes retrieved in the first cycle up to 242 
around 15 oocytes; thereafter the curves flatten. Plotting the live-birth rate within any cycle 243 
against the number of oocytes retrieved in the previous cycle gave a similar pattern (eFigure 244 
2). 245 
 246 
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Using published data23-25 we estimated that the live-birth rate for women conceiving 247 
naturally, who had been trying for 12 menstrual cycles, varied between 58% and 74% 248 
depending on the woman’s age and frequency of intercourse (eTable 9). These estimates are 249 
based on studies that only included women younger than 40. Similar cumulative live-birth 250 
rates were achieved by the fifth or sixth cycle of IVF treatment in women of this age (Table 251 
3), though, in these women, five cycles took a median of 2 years (1st, 3rd quartile: 2, 3). 252 
 253 
Discussion 254 
To our knowledge this is the first study to have linked fresh and frozen embryo transfers to 255 
obtain estimates of live-birth rate within each IVF ovarian stimulation cycle and cumulative 256 
live-birth rates across repeated stimulation cycles. Despite a decline in the success rate within 257 
each cycle as the number of these increased, the cumulative rate across cycles increased up to 258 
the ninth in the whole cohort, those younger than 40 (using their own oocytes) and those 259 
using donor oocytes (irrespective of age). They also increased up to the eighth or ninth in 260 
women aged 40-42, though for women older than 42 (using their own oocytes) the likelihood 261 
of success was low and the cumulative live-birth rate did not appear to clearly increase 262 
beyond the fourth or fifth cycle. For those women able to use donor oocytes, age was 263 
unrelated to success. In those for whom the cause of infertility was related to a male partner 264 
problem, treatment with ICSI or donor sperm made a marked difference in the likelihood of 265 
success, with cumulative rates increasing up to the eighth or ninth cycle, whereas without 266 
treatment rates were lower than in those with other causes of infertility. In women under 40 267 
years with a low oocyte yield in a previous cycle there was benefit in continuing with further 268 
cycles. We also found women under 40 years could achieve cumulative live-birth rates after 269 
five or six cycles that were similar to published live-birth rates achieved naturally within 12 270 
13 
 
menstrual cycles.23-25 It should be noted, however, that, in these women, five cycles took a 271 
median of 2 years. 272 
     273 
Widespread adoption of single embryo transfer has reduced multiple pregnancies and adverse 274 
perinatal outcomes, but has meant that the chance of a live-birth from a single ovarian 275 
stimulation cycle is spread across multiple embryo transfers, which we have assessed here. 276 
Since this method of assessing IVF success combines all embryo transfer events following an 277 
ovulation stimulation into one analysis unit, we were unable to examine the effect of the 278 
number of embryos transferred per event. However, this method of assessing IVF success is 279 
increasingly recommended.5,10-13 Our results show how success rates per embryo transfer 280 
event are misleadingly lower, compared with the rate within each ovarian stimulation cycle. 281 
Furthermore, we have previously shown, using unlinked data from the same population, that 282 
the number of embryos transferred in one event has a relatively modest effect on live-birth 283 
rate, with a difference of 9% in women younger than 40 years and 16% in those aged 40 284 
years or older, comparing double to single embryo transfer.15  285 
 286 
Despite the differences in the definition of cumulative success between our study and the 287 
previous largest study (from the US), in which cumulative live-birth rates were estimated on 288 
the basis of each embryo transfer,5 and differences in health systems between the US and UK, 289 
both studies found age differences in rates and that these were removed with the use of donor 290 
oocytes. In the US study, those with a male cause of infertility had one of the highest 291 
cumulative live-birth rates per embryo transfer, but that study did not examine the effect of 292 
different treatments (ICSI or sperm donation) and it may be that all of those with male cause 293 
infertility in the US receive one of these treatments.  294 
 295 
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The key limitation of all studies looking at cumulative outcomes with repeat IVF is how one 296 
treats those who discontinue treatment. As seen in our data, and in previous studies,5,7 the 297 
extremes of the optimal and conservative estimates often vary markedly, for example in our 298 
data the optimal and conservative estimates were 78.0% and 46.8%, respectively, for the 299 
whole cohort. This is because of the differences between these two, in what they assume 300 
would have been the live-birth rate in those who discontinued IVF, had they continued; for 301 
the optimal estimate this is assumed to be the same as those who did continue, whereas the 302 
conservative estimate it is assumed to be zero. We examined the likelihood that such 303 
discontinuation was due to poor prognosis based on age and previous cycle oocyte retrieval. 304 
These analyses suggested approximately 3% of those who discontinued did so because of 305 
poor prognosis. This small proportion was because although these two were important 306 
predictors of live-birth, few women receiving IVF are older than 40 years (only 15% in our 307 
national population cohort) and most women have a high oocyte yield (median 9 per cycle in 308 
our cohort). However, to account for other factors, for example pre-treatment reproductive 309 
hormone levels, smoking and body mass index (BMI), which have been linked to live-birth 310 
success, 7,22 but that were not available in this study, we assumed a 30% discontinuation due 311 
to poor prognosis. Because of the legal requirement for all UK clinicians to provide data on 312 
all ART patients, the HFEA were able to link cycles to individual women even if they moved 313 
between clinics within the UK. However, treatment abroad would be absent from our data. A 314 
European study, conducted 6 years ago, found very few UK couples travelled for ART to 49 315 
clinics in six (non-UK) European countries with high rates of cross-border patients.26 We 316 
were only able to assess live-birth as an outcome: future studies should also consider 317 
potential adverse effects of continued treatment, including ovarian hyper-stimulation 318 
syndrome and possible increased risk of preterm birth, low birth weight or congenital 319 
anomalies.16,27,28  320 
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 321 
We acknowledge that for some couples the emotional stress of repeat treatments may be 322 
undesirable and the cost of a prolonged treatment course, with several repeat oocyte 323 
stimulation cycles, may be unsustainable for health services, insurers or couples. However, 324 
we think the potential for success with further cycles should be discussed with couples. A 325 
cost-effectiveness analysis is beyond the scope of this study, and the difficulties of 326 
undertaking such analyses for IVF, in which decisions related to how one values a new life 327 
and whether ‘benefits’ and ‘costs’ for both parents and the child should be included, are well-328 
documented.29 The costs of IVF treatment vary between countries, whether publicly or 329 
privately funded, and the treatment type used, but are in the range of $14,000 (£9,000, 330 
€12,000) to $17,000 (£11,000, €15,000) per cycle.1,29,30 These costs exclude assessment prior 331 
to starting IVF and are based on transfer of one fresh embryo. Assuming each addition frozen 332 
embryo transfer costs $4000 to $5000,30 the cost per couple of continuing to six, rather than 333 
having just three cycles, could be as much as $132,000 compared to $66,000 (assuming one 334 
fresh and one frozen transfer per cycle). 335 
 336 
Conclusions 337 
Among women in the UK undergoing IVF, the cumulative prognosis-adjusted live-birth rate 338 
after six cycles was 65.3%, with variations by age and treatment type. These findings support 339 
the efficacy of extending the number of IVF cycles beyond three or four.  340 
 341 
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Figure descriptive titles and legends 440 
Figure 1: Definition of eligible and analysis cohort 441 
Figure 2: Cumulative live-birth rate across all initiated IVF cycles by age and oocyte 442 
source. 443 
The figure shows the prognosis-adjusted estimates of cumulative live-birth rates (i.e. the rate 444 
(shown on the y-axis) is the likelihood of a live-birth across all initiated cycles up to and 445 
including the numbers on the x-axis), with 95% confidence intervals. These are presented for 446 
women in two different age categories at the start of their first IVF treatment cycle (< 40 447 
years and 40-42 years; women in both of these categories used their own oocytes) and also in 448 
women who used donor oocytes (these women cover the full age range). Data for women 449 
aged over 42 at their first treatment cycle are not shown because rates were so low it would 450 
have been difficult to represent them on this same graph (full results for these women are 451 
shown in Table 3). The prognostic-adjusted estimate assumes that 30% of those who 452 
discontinued IVF did so because of poor prognosis and that the live-birth rate in that 30% 453 
would have been zero had they continued. Analyses were completed in 156,947 women 454 
undergoing 257,398 cycles. Log-rank tests indicated a difference between the cumulative 455 
live-births rates for all groups (p < 0.001 for all comparisons). 456 
Figure 3: Cumulative live-birth rate across all initiated IVF cycles by ICSI and sperm 457 
donation. 458 
The figure shows the prognosis-adjusted estimates of cumulative live-birth rates (i.e. the rate 459 
(shown on the y-axis) is the likelihood of a live-birth across all initiated cycles up to and 460 
including the numbers on the x-axis), with 95% confidence intervals. These are shown for 461 
couples without a male cause of infertility, couples with a male cause who were not treated 462 
with ICSI or sperm donation, those with a male cause who were treated with ICSI and those 463 
with a male cause who used sperm donation. The prognostic-adjusted estimate assumes that 464 
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30% of those who discontinued IVF did so because of poor prognosis and that the live-birth 465 
rate in that 30% would have been zero had they continued. Analyses were completed in 466 
156,947 women undergoing 257,398 cycles. Log-rank tests indicated a difference between 467 
the cumulative live-births rates for all groups (p < 0.001 for all comparisons). 468 
Figure 4: Live-birth rate within each single IVF treatment cycle by oocyte retrieval in 469 
first cycle. 470 
The figure shows the live-birth rate within each individual first, second and third treatment 471 
cycle (i.e. for each line the rate on the y-axis is the rate for just that one treatment cycle), 472 
against the number of oocytes retrieved in the first treatment cycle (shown on the x-axis). 473 
Analyses are in 134,903 women aged less than 40 years and using their own oocytes. Box 474 
and whiskers show the central 95% of the distribution of oocytes retrieved in the first cycle, 475 
as well as the median and lower and upper quartiles. 476 
  477 
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Table 1: Characteristics of the analysis cohort of 156,947 women commencing IVF 478 
treatment for infertility in the UK in 2003-2010 (with outcomes assessed up to June 479 
2012).  480 
Characteristic For all cycles combineda For first cycleb 
 
Number of women 
 
 
156,947
  
156,947 
 
Total number of cycles 
    1 
    2 
    3 
    More than 3 
 
93,494 
39,707 
15,507 
8,239
 
(59.6%) 
(25.3%) 
(9.9%) 
(5.2%) 
  
 
Number of cycles 
 
 
257,398
  
156,947 
 
Live-births (% per cycle) 70,093 (27.2%) 46,333 (29.5%) 
Woman’s age (years) 
    Median (1st quartile, 3rd quartile) 
 
35
 
(32, 38) 
 
35 
 
(32, 38) 
Duration of infertility (years) 
    Median (1st quartile, 3rd quartile) 
    Missing  
 
4 
11,165
 
(2, 6) 
(4.3%) 
 
3 
6,586 
 
(2, 5) 
(4.0%) 
Causes of infertility (non-exclusive) 
    Tubal 
    Ovulatory 
    Endometriosis 
    Male cause  
 
46,535 
34,473 
15,889 
105,014
 
(18.1%) 
(13.4%) 
(6.2%) 
(40.8%) 
 
28,181 
21,582 
9,654 
63,023 
 
(18.0%) 
(13.8%) 
(6.1%) 
(40.2%) 
Treated with ICSI 123,009 (47.8%) 68,608 (43.7%) 
Treated with sperm donation 8,067 (3.1%) 4,781 (3.05%) 
Treated with oocyte donation 7,223 (2.8%) 3,587 (2.3%) 
Oocytes retrieved (own) 
    Median (1st quartile, 3rd quartile) 
9 (5, 13) 9 (5, 13) 
Embryo transfer events per cycle 
    No embryos transferred 
    Fresh embryo transfer only 
    Fresh and frozen embryo transfer 
 
31,738 
199,713 
25,947
 
(12.3%) 
(77.6%) 
(10.1%) 
 
20,794 
119,462 
16,691 
 
(13.3%) 
(76.1%) 
(10.6%) 
 
Number of embryo transfer events 
 
 
257,581
  
157,043 
 
Number of embryos transferred per 
embryo transfer eventc  
    1 
    2 
    3-4 
 
 
44,330 
201,888 
11,363
 
 
(17.2%) 
(78.4%) 
(4.4%) 
 
 
29,942 
122,483 
4,618 
 
 
(19.1%) 
(78.0%) 
(3.0%) 
a The unit of analysis here is cycle (with results the average across all cycles per woman)  481 
b As this is just one cycle the unit of analysis is the women at their first treatment cycle 482 
c As there are a variable number of transfer events per treatment cycle (which includes all 483 
subsequent fresh and frozen transfer events) the % is per the number of transfer events (not 484 
per cycle)  485 
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Table 2: Within initiated treatment cycle live-birth rates and cumulative live-birth rate across all cycles in 156,947 women undergoing 486 
257,398 cycles of IVF 487 
 488 
Cycle 
number 
N Cycles N live-
births 
Live-birth rate 
within each cycle 
% (95%CI) 
Cumulative live-birth across all cycles using different estimates % (95%CI) 
Optimal estimatea Age adjusted 
estimateb 
Prognostic-
adjusted estimatec 
Conservative 
estimated 
1st 156,947 46,333 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 29.5 (29.3, 29.7) 
2nd 63,453 15,825 24.9 (24.6, 25.3) 47.1 (46.8, 47.4) 46.7 (46.4, 47.0) 45.1 (44.9, 45.4) 40.5 (40.3, 40.8) 
3rd 23,746 5,358 22.6 (22.0, 23.1) 59.0 (58.7, 59.4) 58.3 (57.9, 58.6) 54.3 (54.0, 54.6) 44.6 (44.4, 44.9)
4th 8,239 1,690 20.5 (19.6, 21.4) 67.4 (67.0, 67.9) 66.4 (66.0, 66.9) 59.8 (59.4, 60.1) 46.1 (45.8, 46.3) 
5th 3,012 553 18.4 (17.0, 19.7) 73.4 (72.8, 74.0) 72.2 (71.6, 72.7) 63.1 (62.6, 63.5) 46.6 (46.3, 46.8) 
6th 1,162 202 17.4 (15.2, 19.6) 78.0 (77.3, 78.8) 76.7 (76.0, 77.5) 65.3 (64.8, 65.8) 46.8 (46.5, 47.0) 
7th 458 79 17.2 (13.8, 20.7) 81.8 (80.8, 82.8) 80.5 (79.5, 81.5) 66.8 (66.2, 67.4) 46.9 (46.7, 47.2) 
8th 199 37 18.6 (13.2, 24.0) 85.2 (83.9, 86.5) 83.7 (82.4, 85.0) 68.0 (67.3, 68.7) 46.9 (46.7, 47.2) 
9th 83 13 15.7 (7.8, 23.5) 87.5 (85.9, 89.1) 86.3 (84.7, 87.9) 68.7 (68.0, 69.5) 46.9 (46.7, 47.2) 
 489 
a The optimal estimate assumes that the cumulative live-birth rate in women who discontinue IVF without a live-birth, if they had continued, 490 
would have been equal to the rate in women who continued to have further IVF. That is it assumes that 0% of women who discontinued IVF did 491 
so because of poor prognosis that would have affected their live-birth success had they continued. 492 
b The age-adjusted estimate assumes that the cumulative live-birth rate in women who discontinued IVF, if they had continued, would have been 493 
equal to the rate in women who were the same age at the start of treatment, and who continued to have further IVF. These results suggested 494 
approximately 3% of women who discontinued did so because of poor prognosis and would have had a live-birth rate of zero, had they 495 
continued. 496 
c The prognostic-adjusted estimate assumes that 30% of women who discontinued IVF did so because of poor prognosis and would have had a 497 
live-birth rate of zero, had they continued. 498 
d The conservative estimate assumes that the cumulative live-birth rate in all women who discontinued IVF would have been zero, had they 499 
continued. That is it assumes that 100% of women who discontinued did so because of poor prognosis and would have had a live-birth rate of 500 
zero, had they continued. 501 
Note it is not possible to calculate an oocyte-adjusted estimate for the whole cohort due to the presence of women using donor oocytes.502 
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Table 3: Within initiated treatment cycle live-birth rates and cumulative live-birth rate across all cycles in 153,360 women, undergoing 503 
250,175 cycles of IVF using their own oocytes, stratified by age at first ovarian stimulation cycle. 504 
 505 
Cycle 
number 
N Cycles N live-
births 
Live-birth rate 
within each cycle 
% (95%CI) 
Cumulative live-birth across all cycles using different estimates % (95%CI) 
Optimal estimatea Previous oocyte 
yield-adjusted 
estimateb 
Prognostic-
adjusted estimatec 
Conservative 
estimated 
Aged less than 40 years      
1st 133,379 43,019 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 32.3 (32.0, 32.5) 
2nd 53,568 14,532 27.1 (26.8, 27.5) 50.6 (50.3, 50.9) 50.7 (50.4, 51.1) 48.7 (48.4, 49.0) 44.3 (44.0, 44.5) 
3rd 19,719 4,793 24.3 (23.7, 24.9) 62.6 (62.3, 63.0) 62.7 (62.3, 63.1) 58.0 (57.7, 58.4) 48.6 (48.4, 48.9) 
4th 6,641 1,419 21.4 (20.4, 22.4) 70.6 (70.1, 71.1) 70.5 (70.1, 71.0) 63.3 (62.9, 63.7) 50.1 (49.8, 50.3) 
5th 2,357 449 19.0 (17.5, 20.6) 76.2 (75.6, 76.8) 76.0 (75.4, 76.6) 66.4 (66.0, 66.9) 50.6 (50.3, 50.8) 
6th 882 150 17.0 (14.5, 19.5) 80.3 (79.5, 81.0) 80.1 (79.3, 80.8) 68.4 (67.8, 68.9) 50.7 (50.5, 51.0) 
7th 335 58 17.3 (13.3, 21.4) 83.7 (82.7, 84.7) 83.4 (82.4, 84.4) 69.8 (69.1, 70.4) 50.8 (50.5, 51.1) 
8th 131 25 19.1 (12.4, 25.8) 86.8 (85.4, 88.2) 86.5 (85.1, 87.9) 70.9 (70.1, 71.6) 50.9 (50.6, 51.1) 
9th 51 10 19.6 (8.7, 30.5) 89.4 (87.6, 91.2) 88.8 (87.2, 90.3) 71.6 (70.8, 72.5) 50.9 (50.6, 51.2) 
Aged 40 to 42 years      
1st 15,561 1,914 12·3 (11·8, 12·8) 12·3 (11·8, 12·8) 12·3 (11·8, 12·8) 12·3 (11·8, 12·8) 12.3 (11.8, 12.8) 
2nd 6,671 671 10·1 (9·3, 10·8) 21·1 (20·3, 21·9) 20·8 (20·0, 21·6) 19.8 (19.1, 20.6) 16.8 (16.3, 17.4) 
3rd 2,579 223 8·6 (7·6, 9·7) 27·9 (26·8, 29·1) 27·6 (26·5, 28·7) 24.7 (23.8, 25.6) 18.5 (17.8, 19.1) 
4th 884 69 7·8 (6·0, 9·6) 33·6 (31·9, 35·2) 33·0 (31·4, 34·7) 28.0 (26.9, 29.2) 19.0 (18.4, 19.6) 
5th 301 16 5·3 (2·8, 7·9) 37·4 (34·8, 39·4) 36·5 (34·3, 38·8) 29.7 (28.3, 31.1) 19.1 (18.5, 19.8) 
6th 130 9 6·9 (2·6, 11·3) 41·5 (38·0, 44·9) 40·5 (37·3, 43·8) 31.5 (29.7, 33.3) 19.2 (18.6, 19.8) 
7th 60 2 3·3† 43·4 (39·1, 47·7) 42·4 (38·4, 46·3) 32.2 (30.2, 34.2) 19.2 (18.6, 19.9) 
8th 36 1 2·8† 45·0 (39·8, 50·1) 43·4 (39·1, 47·6) 32.7 (30.5, 34.9) 19.2 (18.6, 19.9)
9th 20 0 0·0† 45·0 (39·8, 50·1) 43·4 (39·1, 47·6) 32.7 (30.5, 34.9) 19.2 (18.6, 19.9) 
Aged more than 42 years      
1st 4,420 164 3·7 (3·2, 4·3) 3·7 (3·2, 4·3) 3·7 (3·2, 4·3) 3·7 (3·2, 4·3) 3.7(3.2, 4.3) 
2nd 1,578 52 3·3 (2·4, 4·2) 6·9 (5·9, 7·9) 6·9 (5·9, 7·9) 6.3 (5.4, 7.2) 4.9 (4.3, 5.6) 
3rd 509 17 3·3 (1·8, 4·9) 10·0 (8·2, 11·7) 9·8 (8·1, 11·5) 8.3 (7.1, 9.6) 5.4 (4.7, 6.0) 
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4th 160 2 1·3† 11·1 (8·8, 13·4) 10·1 (8·5, 11·8) 8.9 (7.4, 10.5) 5.5 (4.8, 6.2) 
5th 67 3 4·5† 15·1 (10·2, 20·0) 14·2 (10·7, 17·7) 10.7 (8.2, 13.2) 5.5 (4.8, 6.2) 
6th 24 0 0·0† 15·1 (10·2, 20·0) 14·2 (10·7, 17·7) 10.7 (8.2, 13.2) 5.6 (4.9, 6.3) 
7th 10 2 20·0† 32·1 (10·7, 53·5) 22·3 (14·0, 30·5) 15.9 (8.5, 23.2) 5.6 (4.9, 6.3) 
8th 5 0 0·0† 32·1 (10·7, 53·5) 22·3 (14·0, 30·5) 15.9 (8.5, 23.2) 5.6 (4.9, 6.3) 
9th 4 0 0·0† 32·1 (10·7, 53·5) 22·3 (14·0, 30·5) 15.9 (8.5, 23.2) 5.6 (4.9, 6.3) 
 506 
a The optimal estimate assumes that the cumulative live-birth rate in women who discontinue IVF without a live-birth, if they had continued, 507 
would have been equal to the rate in women who continued to have further IVF. That is it assumes that 0% of women who discontinued IVF did 508 
so because of poor prognosis that would have affected their live-birth success had they continued. 509 
b The previous oocyte yeild-adjusted estimate assumes that the cumulative live-birth rate in women who discontinued IVF, if they had continued, 510 
would have been equal to the rate in women who had the same oocyte yield in the immediately previous ovarian stimulation treatment, and who 511 
continued to have further IVF. These results suggested approximately 3% of women who discontinued did so because of poor prognosis and 512 
would have had a live-birth rate of zero, had they continued. 513 
c The prognostic-adjusted estimate assumes that 30% of women who discontinued IVF did so because of poor prognosis and would have had a 514 
live-birth rate of zero, had they continued. 515 
d The conservative estimate assumes that the cumulative live-birth rate in all women who discontinued IVF would have been zero, had they 516 
continued. That is it assumes that 100% of women who discontinued did so because of poor prognosis and would have had a live-birth rate of 517 
zero, had they continued. 518 
Note it is not possible to calculate an age-adjusted estimate these age stratified analyses and there is too little age variation within the ages 519 
stratified groups to further adjust for age. 520 
† These are cycles for which there was fewer than six live births and for these standard errors and hence confidence intervals could not be 521 
calculated 522 
All UK assisted reproductive therapy
treatment 1 January 2003 to 30 June 2012
235,000 women, 385,382 cycles
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Treatment in 2011 and 2012
36,775 women, 71,649 cycles
Treatment subsequent to
an IVF live birth
0 women, 12,364 cycles
Eligible cohort
157,475 women, 257,665 cycles
Implausible linkage information
(first treatment frozen embryo transfer)
528 women, 267 cycles
Analysis cohort
156,947 women, 257,398 cycles
1 2 3 4 5 6 7 8 9
Cycle number
Cu
mu
lat
ive
 liv
e b
irth
 ra
te 
ac
ros
s t
rea
tm
en
t c
yc
les
0%
20%
40%
60%
80%
100%
●
●
●
●
●
●
● ● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
Donor oocytes, all ages
Own oocytes and age < 40
Own oocytes and age 40−42
133,379  53,568  19,719   6,641   2,357     882     335     131      51
15,561  6,671  2,579    884    301    130     60     36     20
4,420 1,578   509   160    67    24    10     5     4
3,587 1,636   939   554   287   126    53    27     8
Number of women
Own oocytes and age < 40
Own oocytes and age 40−42
Own oocytes and age > 42
Donor oocytes, all ages
1 2 3 4 5 6 7 8 9
Cycle number
Cu
mu
lat
ive
 liv
e b
irth
 ra
te 
ac
ros
s t
rea
tm
en
t c
yc
les
0%
20%
40%
60%
80%
100%
●
●
●
●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ● ●
Male cause, partner sperm, no ICSI
No male cause
Male cause, partner sperm and ICSI
Male cause, donor sperm
93,924 37,161 13,645  4,680  1,765    690    277    119     51
12,536  4,207  1,478    471    148     70     30     15      3
48,016 21,006  8,203  2,911  1,015    377    141     57     24
2,471 1,079   420   177    84    25    10     8     5
Number of women
No male cause
Male cause, partner sperm, no ICSI
Male cause, partner sperm and ICSI
Male cause, donor sperm
0 5 10 15 20 25 30
Oocytes retrieved in first cycle
Liv
e b
irth
 ra
te 
wi
thi
n t
rea
tm
en
t c
yc
le
0%
10%
20%
30%
40%
50% Cycle 1: 133,379 women
Cycle 2: 53,556 women
Cycle 3: 19,715 women
